Over the past year, Congress has spent a conspicuously large amount of its limited legislative time in efforts to constrain the activities of pharmacy benefit managers, or PBMs. Four different House committees and three Senate Committees have held hearings or marked up proposed legislation that addressed PBMs. With many must-do items and looming deadlines (such as avoiding a government shutdown, for example) and not a lot of legislative days on its calendar, it’s worth asking why it has focused on this industry. The flurry of motion on the issue suggests it has little to do with actually reducing drug prices.
However, government agencies have acknowledged that efforts to rein in PBMs would do nothing to save taxpayers or patients money: Studies published by both the Government Accountability Office and the HHS Office of the Inspector General found that the rebates PBMs negotiate are passed along to plan sponsors in Part D to lower the costs of premiums for beneficiaries and taxpayers alike.
https://www.realclearmarkets.com/ar...inking_in_drug-price_negotiations_979967.html
However, government agencies have acknowledged that efforts to rein in PBMs would do nothing to save taxpayers or patients money: Studies published by both the Government Accountability Office and the HHS Office of the Inspector General found that the rebates PBMs negotiate are passed along to plan sponsors in Part D to lower the costs of premiums for beneficiaries and taxpayers alike.
https://www.realclearmarkets.com/ar...inking_in_drug-price_negotiations_979967.html